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Abstract
Background: While the Albizia adianthifolia (Schumach.) W. Wright (Fabaceae) is a traditional herb largely used in the
African traditional medicine as analgesic, purgative, antiinflammatory, antioxidant, antimicrobial, memory-enhancer,
anxiolytic and antidepressant drug, there are no scientific data that clarify the anxiolytic and antidepressant-like effects
in 6-hydroxydopamine (6-OHDA)-lesioned animal model of Parkinson’s disease. This study was undertaken in order to
identify the effects of aqueous extract of A. adianthifolia leaves on 6-hydroxydopamine-induced anxiety, depression
and oxidative stress in the rat amygdala.
Methods: The effect of the aqueous extract of A. adianthifolia leaves (150 and 300 mg/kg, orally, daily, for 21 days) on
anxiety and depression was assessed using elevated plus-maze and forced swimming tests, as animal models of
anxiety and depression. Also, the antioxidant activity in the rat amygdala was assessed using assessed using superoxide
dismutase, glutathione peroxidase and catalase specific activities, the total content of the reduced glutathione, protein
carbonyl and malondialdehyde levels. Statistical analyses were performed using by one-way analysis of variance
(ANOVA). Significant differences were determined by Tukey’s post hoc test. F values for which p < 0.05 were regarded as
statistically significant. Pearson’s correlation coefficient and regression analysis were used in order to evaluate the
connection between behavioral measures, the antioxidant defence and lipid peroxidation.
Results: 6-OHDA-lesioned rats exhibited the following: decrease of the exploratory activity, the percentage of the time
spent and the number of entries in the open arm within elevated plus-maze test and decrease of swimming time and
increase of immobility time within forced swimming test. Administration of the aqueous extract significantly exhibited
anxiolytic- and antidepressant-like effects and also antioxidant potential in the rat amygdala.
Conclusions: Our results suggest that the aqueous extract ameliorates 6-OHDA-induced anxiety and depression by
attenuation of the oxidative stress in the rat amygdala. These pieces of evidence accentuate its use in traditional
medicine.
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Background
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by a massive and progressive degeneration
of the dopaminergic neurons in the substantia nigra (SN)
[1]. About 30-40 % of people with PD experience a
depressive disorder [2] and most have symptoms of
depression at some stage [3]. Up to 40 % have symptoms
of anxiety and around 30 % experience an anxiety disorder
[4]. About 40 % of people with PD and depression also
have an anxiety disorder. The link between PD, depres-
sion and anxiety is complex. Its neuropathology in-
cludes the degeneration of dopaminergic nigrostriatal
pathway, which is a cumulative effect of glutathione de-
pletion, iron deposition, increased lipid peroxidation,
oxidative DNA damage, mitochondrial dysfunction,
excitotoxicity and alterations in antioxidant enzymes
activities [5, 6].
Previous studies indicated the role of the amygdala in
regulating anxiety, depression responses and fear memory
in both humans and animals [7]. Furthermore, the dopa-
mine neurotransmitter system is involved in a large num-
ber of higher brain functions, and regulates the activity of
the amygdala [8].
The most widely used animal models of PD involve
intracranial infusion of the neurotoxin 6-OHDA directly
into the ascending dopaminergic forebrain bundle,
thereby inducing severe dopaminergic neuronal degener-
ation associated with profound deficits in feeding, drink-
ing, sensorimotor and learning functions [9, 10].
Oxidative stress mechanism gets more prominent in
the process of ageing, thus is the most important risk
factor for developing PD [11]. Mitochondrial dysfunction
along with damaged proteins and lipids due to oxidative
stress plays a key role in PD pathological process [12].
A. adianthifolia is a medicinal plant widely distributed
in Africa and in Cameroon. Aqueous and ethanol
extracts of A. adianthifolia (stem bark) used in Southern
Africa to treat memory loss and Alzheimer’s disease,
have been screened for acetylcholinesterase inhibitory
activity [13]. Kim et al. [14] reported that the aqueous
extract of A. julibrissin had anxiolytic-like effects in rats
as assessed using the elevated plus-maze test. Also, a
recent study indicated that julibroside C1 extracted from
A. julibrissin stem bark produced potent anxiolytic-like
effects in mice [15]. Previously published data by our
group demonstrated by HPLC analyses that among
flavones, the main constituent of the aqueous extract of
A. adianthifolia leaves is apigenin, responsible for the
observed cognitive-enhancing effects in the 6-OHDA-
lesion rodent model of PD [16]. Moreover, it was
claimed that saponins from Albizia lebbeck could be
used in treatment of Alzheimer’s and PD [17].
In this study we examined the effects of the aqueous ex-
tract of A. adianthifolia leaves on anxiety and depression
levels, as well as the importance of the aqueous extract in
oxidative stress status in the amygdala of 6-OHDA-
treated rats. Correlation between the anxiety-depression-
like behaviors and the levels of the main oxidative stress
markers from the amygdala of 6-OHDA-treated rats, as a
result of the aqueous extract administration was also
investigated.
Methods
Plant material and plant extract
Albizia adianthifolia leaves were collected in Elounden,
near Yaoundé (Cameroon) in June 2010 and identified by
Dr. Nolé Tsabang at the National Herbarium, Yaoundé
where a voucher specimen (N° HNC 29997) was regis-
tered and deposited for ready reference. All locations
where the plant was collected were not privately-owned or
protected in any way and the field studies did not involve
endangered or protected species. A. adianthifolia leaves
were air dried and pulverized into fine powder. Five hun-
dred grams of pulverized sample material was macerated
in 5 L of distilled water for 48 h at room temperature and
shaking regularly. Then the mixture was filtered through
Whatman filter paper no. 3. The aqueous extract was then
lyophilized to obtain powder used for our various tests.
The given powder yield was 4 % (v/w). The dried extract
was dissolved in distilled water and administered by gas-
tric gavage to animals at the doses of 150 and 300 mg/kg
body weight.
Animals
60 male Wistar rats weighing 350 ± 50 g at the start of the
experiment were used. The animals were housed in a
temperature and light-controlled room (22 °C, a 12-h
cycle starting at 08:00 h) and were fed and allowed to
drink water ad libitum. Rats were treated in accordance
with the guidelines of animal bioethics from the Act on
Animal Experimentation and Animal Health and Welfare
from Romania and all procedures were in compliance with
Directive 2010/63/EU of the European Parliament and of
the Council of 22 September 2010 on the protection of
animals used for scientific purposes. The protocol was
approved by the Committee on the Ethics of Animal
Experiments of the Alexandru Ioan Cuza University of
Iasi, Romania (Permit Number: 1502723). All surgery was
performed under sodium pentobarbital anesthesia, and all
efforts were made to minimize animal suffering and to re-
duce the number of animal used. For the elevated plus-
maze and forced swimming tests were employed the same
group of rats.
Drugs
6-Hydroxydopamine (free base, 6-OHDA), desipramine,
sodium pentobarbital, diazepam hydrochloride and
tramadol (Sigma-Aldrich, Germany) were dissolved in
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an isotonic solution (0.9 % NaCl). All other reagents
were purchased from Sigma-Aldrich, Germany.
Neurosurgery
All surgical procedures were conducted under aseptic
conditions, under sodium pentobarbital (50 mg/kg
b.w., i.p.,) anesthesia. Rats were mounted in the
stereotaxic apparatus with the nose oriented 11°
below horizontal zero plane. Thereafter, the animals
received a right-unilaterally intranigral injections of
5 μL of 0.9 % saline containing 2.5 μg/μL 6-OHDA
(free base) and 0.2 % ascorbic acid (w/v) at a rate of
1 μL/min at the following coordinates: 5.5 mm
posterior to bregma; 2.0 mm lateral to the midline;
7.4 mm ventral to the surface of the cortex, accord-
ing to the rat brain atlas [18]. All rats sustaining 6-
OHDA lesion were pretreated with desipramine
(25 mg/kg, i.p. in saline) 30 min before anesthesia in
order to protect noradrenergic system. The rats in
the control group (sham-operated) were given 5 μL
of 0.9 % saline - 0.2 % ascorbic acid administered in
a similar manner as the solution containing 6-
OHDA.
Postoperative care
Recovery from anesthesia took approximately 6 h. The
rats were kept in well-ventilated room at 22 °C in indi-
vidual cages till they gained full consciousness and were
then housed together in a group of five animals per cage.
Food was kept inside the cages during the first week so
that animals could easily access it without any physical
trauma due to surgical intervention.
Drug administration
The rats were divided into 6 groups (10 per group): (1)
control group (sham-operated, received orally distilled
water treatment); (2) Diazepam alone-treated group
(sham-operated, DZP, 1.5 mg/kg); (3) Tramadol alone-
treated group (sham-operated, TRM, 10 mg/kg); (4) 6-
OHDA-lesioned group, as negative control, received
orally distilled water treatment; (5) 6-OHDA-lesioned
group received orally 150 mg/kg of the aqueous extract
of A. adianthifolia leaves treatment (6-OHDA + AE
(150 mg/kg)) and (6) 6-OHDA-lesioned group received
orally 300 mg/kg of the aqueous extract of A. adianthi-
folia leaves treatment (6-OHDA + AE (300 mg/kg)).
The administration of the distilled water and the aqueous
extract was performed orally by gastric gavage with rat
biomedical needles (length 7.62 cm, ball diameter 4 mm,
straight). The volume administered was 10 mL/kg of body
weight, daily, for 21 consecutive days after neurosurgery.
The aqueous extract doses (150 mg/kg and 300 mg/kg)
used in this experiment were chosen since they have been
demonstrated by our group to provide significant effects
on memory formation and antioxidant profile [16]. Diaze-
pam hydrochloride (Sigma-Aldrich, Germany) and trama-
dol (Sigma-Aldrich, Germany) were used as positive
controls and were injected intraperitoneally (i.p.) in a
volume of 1 mL/kg in the sham-operated rats, 1 h before
behaviorally tested.
Rotational behavior
The animals were tested for rotational behavior by per-
golide (0.5 mg/kg, b.w., s.c., Sigma-Aldrich, Germany)
1 week after the 6-OHDA injection. The drug pergolide
functions as a dopamine receptor agonist for D2 and D1
receptors and as a ligand to serotonin 5-HT1A, 5-HT1B,
5-HT2A, 5-HT2B, and 5-HT2C receptors [19]. Also, it
was argued that pergolide induced contralateral rota-
tion in animals with striatal lesion after systemic
administration [20]. Briefly, 1 min after pergolide injec-
tion, full rotations were counted in a cylindrical con-
tainer (a diameter of 33 cm and a height of 35 cm) at
10 min intervals for 60 min in a quiet isolated room.
Rotations in the ipsilateral and contralateral directions
were counted separately and the analyses were based
on the net scores (contralateral minus ipsilateral rota-
tions) recorded for 60 min [21].
Elevated plus-maze task
Behavior in the elevated plus-maze (EPM) is largely used
to assess exploration, anxiety and motor behavior. The
EPM consists of four arms, 49 cm long and 10 cm wide,
elevated 50 cm above the ground. Two arms were
enclosed by walls 30 cm high and the other two arms
were exposed. The illumination was set at 400 lx.
30 min after the aqueous extract of A. adianthifolia
leaves administration, each rat was placed in the center
of the maze facing one closed arm. Behavior was ob-
served for 5 min, and the time spent and number of en-
tries into the open and enclosed arms was counted [22].
The percentages of time spent in the open arms (time
spent in the open arms/time spent in all arms x 100)
were calculated. In addition, the total number of open-
and enclosed-arm entries, which indicates the locomo-
tors activity of animals [23], was measured. An entry
was defined as an animal placing all four paws into an
arm, and no time was recorded when the animal was in
the central area. The maze was cleaned with 10 % etha-
nol solution and dried with a cloth before the next ani-
mal was tested. Behavioral data were automatically
tracked and recorded using ANY-maze behavioral soft-
ware (Stoelting Co., USA, version 4.5).
Forced swimming test (FST)
The possible antidepressant effects of the aqueous ex-
tract of A. adianthifolia leaves were assessed, basically
using the same method described by Campos et al. [24]
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but with modification. On the first day of the experi-
ments (pretest session), rats were individually placed
into cylindrical recipients (diameter 30 cm, height
59 cm) containing 25 cm of water at 26 ± 1 °C. The ani-
mals were left to swim for 15 min before being removed,
dried and returned to their cages. The procedure was re-
peated 24 h later, in a 6 min swim session (test session),
30 min after the aqueous extract of A. adianthifolia
leaves administration. During the test session, the fol-
lowing behavioral responses were recorded: (1) immobil-
ity (time spent floating with the minimal movements to
keep the head above the water) and (2) swimming (time
spent with active swimming movements).
Biochemical parameter assay
Three weeks after the administration of aqueous extract
of A. adianthifolia leaves in 6-OHDA-lesioned animals
groups, all rats were deeply anesthetized (using sodium
pentobarbital, 100 mg/kg b.w., i.p., Sigma-Aldrich,
Germany) and decapitated and whole brains were re-
moved. Bilateral amygdala was carefully excised. Each
of the amygdala samples were weighted and homoge-
nized (1:10) with Potter Homogenizer coupled with
Cole-Parmer Servodyne Mixer in ice-cold 0.1 M potas-
sium phosphate buffer (pH 7.4), 1.15 % KCl. The hom-
ogenate was centrifuged (15 min at 960 x g) and the
supernatant was used for assays of SOD, GPX, CAT
specific activities, total content of reduced GSH, pro-
tein carbonyl and MDA levels.
Determination of SOD activity
The activity of superoxide dismutase (SOD, EC 1.15.1.1)
was assayed by monitoring its ability to inhibit the photo-
chemical reduction of nitroblue tetrazolium (NBT). Each
1.5 mL reaction mixture contained 100 mM TRIS/HCl
(pH 7.8), 75 mM NBT, 2 μM riboflavin, 6 mM EDTA, and
200 μL of supernatant. Monitoring the increase in absorb-
ance at 560 nm followed the production of blue formazan.
One unit of SOD is defined as the quantity required to
inhibit the rate of NBT reduction by 50 % as previously
described by Winterbourn et al. [25]. The enzyme activity
is expressed as units/mg protein.
Determination of GPX activity
Glutathione peroxidase (GPX, E.C. 1.11.1.9) activity was
analyzed by a spectrophotometric assay. A reaction mix-
ture consisting of 1 mL of 0.4 M phosphate buffer
(pH 7.0) containing 0.4 mM EDTA, 1 mL of 5 mM
NaN3, 1 mL of 4 mM glutathione (GSH), and 200 μL of
supernatant was pre-incubated at 37 °C for 5 min. Then
1 mL of 4 mM H2O2 was added and incubated at 37 °C
for further 5 min. The excess amount of GSH was quan-
tified by the DTNB method as previously described by
Sharma and Gupta [26]. One unit of GPX is defined as
the amount of enzyme required to oxidize 1 nmol GSH/
min. The enzyme activity is expressed as units/mg
protein.
Determination of CAT activity
Catalase (CAT, EC 1.11.1.6) activity was assayed follow-
ing the method of Sinha [27]. The reaction mixture con-
sisted of 150 μL phosphate buffer (0.01 M, pH 7.0),
100 μL supernatant. Reaction was started by adding
250 μL H2O2 0.16 M, incubated at 37 °C for 1 min and
reaction was stopped by addition of 1.0 mL of dichro-
mate: acetic acid reagent. The tubes were immediately
kept in a boiling water bath for 15 min and the green
colour developed during the reaction was read at
570 nm on a spectrophotometer. Control tubes, devoid
of enzyme, were also processed in parallel. The enzyme
activity is expressed as μmol of H2O2 consumed/min/mg
protein.
Total content of reduced GSH
Glutathione (GSH) was measured following the method
of Fukuzawa and Tokumura [28]. 200 μL of supernatant
was added to 1.1 mL of 0.25 M sodium phosphate buffer
(pH 7.4) followed by the addition of 130 μL DTNB
0.04 %. Finally, the mixture was brought to a final vol-
ume of 1.5 mL with distilled water and absorbance was
read in a spectrophotometer at 412 nm and results were
expressed as μg GSH/μg protein.
Determination of protein carbonyl level
The extent of protein oxidation in the amygdala was
assessed by measuring the content of protein carbonyl
groups, using 2,4- dinitrophenylhydrazine (DNPH) de-
rivatization as described by Oliver et al. [29] and follow-
ing the indications of Luo and Wehr [30]. Basically, the
supernatant fraction was divided into two equal aliquots
containing approximately 2 mg of protein each. Both ali-
quots were precipitated with 10 % trichloroacetic acid
(TCA, w/v, final concentration). One sample was treated
with 2 N HCl, and the other sample was treated with an
equal volume of 0.2 % (w/v) DNPH in 2 N HCI. Both
samples were incubated at 25 °C and stirred at 5 min in-
tervals. The samples were then reprecipitated with 10 %
TCA (final concentration) and subsequently extracted
with ethanol-ethyl acetate (1:1, v/v) and then reprecipi-
tated at 10 % TCA. The pellets were carefully drained
and dissolved in 6 M guanidine hydrochloride with
20 mM sodium phosphate buffer, pH 6.5. Insoluble deb-
ris was removed by centrifugation at 13 000 x g at 4 °C.
The absorbance at 370 nm of the DNPH-treated sample
versus the HCl control was recorded, and the results are
expressed as nmols of DNPH incorporated/mg of protein
based on an average absorptivity of 21.0 mM−1 cm−1 for
most aliphatic hydrazones.
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Determination of MDA level
Malondialdehyde (MDA), which is an indicator of lipid
peroxidation, was spectrophotometrically measured by
using the thiobarbituric acid assay [31]. 200 μL of super-
natant was added and briefly mixed with 1 mL of 50 %
trichloroacetic acid in 0.1 M HCl and 1 mL of 26 mM
thiobarbituric acid. After vortex mixing, samples were
maintained at 95 °C for 20 min. Afterwards, samples
were centrifuged at 960 x g for 10 min and supernatants
were read at 532 nm. A calibration curve was con-
structed using MDA as standard and the results were
expressed as nmol/mg protein.
Estimation of protein concentration
Estimation of protein was done using a bicinchoninic
acid (BCA) protein assay kit (Sigma-Aldrich, Germany).
The BCA protein assay is a detergent-compatible formu-
lation based on BCA for the colorimetric detection and
quantification of total protein, as previously described by
Smith et al. [32].
DNA fragmentation
Total DNA was isolated from the amygdala samples
using the phenol/chloroform method as previously de-
scribed by Ausubel et al. [33]. 50 mg tissue sample was
digested overnight at 37 °C in 0.6 mL digestion buffer
(100 mM NaCl, 10 mM TRIS/HCl, 25 mM EDTA
pH 8.00, 0.5 % SDS) containing 0.1 mg/mL proteinase K
(Boehringer Mannheim, Germany). The digest was ex-
tracted with equal volumes of TRIS-saturated phenol
(pH 8.0) (Roti-phenol, Roth, Germany) by shaking gently
to completely mix the two phases. The phases were then
separated by centrifugation and the aqueous phase
(approx. 0.6 ml) was transferred to another tube avoid-
ing interphase. The DNA was then precipitated by add-
ing 300 μL of 7.5 M ammonium acetate (i.e., 1/2 of
volume) and equal volume of 100 % ethanol at room
temperature and shaken gently to mix thoroughly. DNA
seen as stringy precipitate was pelleted by centrifugation
and washed with 70 % ethanol to remove traces of
sodium dodecyl sulfate and phenol. After removing
ethanol, DNA was air-dried for 10 min at room
temperature and suspended with 50 μL of 10 mM TRIS
(pH 8.0), 1 mM EDTA. DNA content was determined
spectrophotometrically by absorbance at 260 nm and
the purity of the DNA was confirmed by a ratio >1.8 at
260/280 nm. Approximately 0.5 mg genomic DNA was
dissolved in a mixture of 10 μL of TRIS-EDTA and
5 μL of gel loading buffer (0.25 % bromophenol blue,
0.25 % xylene cyanol FF, 30 % (v/v) glycerol) and then
loaded on a 1.5 % agarose gel in TRIS-boric acid-EDTA
(TBE) buffer (89 mM Tris boric acid, 2 mM EDTA,
pH 8.0). Electrophoresis was performed in TBE at
120 V until sufficient resolution was obtained. A 1-kb
DNA ladder (New England Biolabs, Ipswich, MA) was
used as a standard size marker. The bands were visual-
ized by ethidium bromide staining under UV light.
6-OHDA-lesion control
Pergolide-induced rotational behavior test was employed
to validate unilateral damage to dopamine nigrostriatal
neurons. The pergolide results confirm the impairment
of the dopaminergic system as previously described [16].
Statistical analysis
Behavioral scores within elevated plus-maze and forced
swimming tests and biochemical data were analyzed by
one-way analysis of variance (ANOVA) using XLSTAT
version 2012. 1.01 software, Addinsoft. All results are
expressed as mean ± S.E.M. F values for which p < 0.05
were regarded as statistically significant. Significant
differences were determined by Tukey’s post hoc test.
Pearson’s correlation coefficient and regression analysis
were used in order to evaluate the connection between
behavioral measures, the antioxidant defence and lipid
peroxidation.
Results
Effect pergolide on rotational behavior
Pergolide-induced rotational behavior was analyzed to
assess the unilateral degeneration of the dopamine
nigrostriatal neurons. Control group did not show any
significant bias in turning behavior after receiving pergo-
lide injection. In contrast, rats exhibited contralateral
rotational behavior following pergolide challenge in
1 week after the unilateral administration of 6-OHDA
into the SN. In the rotational behavioral test, ANOVA
revealed an attenuation of asymmetric motor behavior
(F(3,36) = 20.03, p < 0.0001) in experimental animals
treated with the aqueous extract of A. adianthifolia
leaves (150 and 300 mg/kg) as compared to control
group (Fig. 1). Additionally, Tukey’s post hoc analysis
revealed a significant difference between the control and
6-OHDA groups (p < 0.0001), control and 6-OHDA +AE
(150 mg/kg) groups (p < 0.0001), control and 6-OHDA
+ AE (300 mg/kg) groups (p < 0.0001), 6-OHDA and 6-
OHDA + AE (150 mg/kg) groups (p < 0.001), 6-OHDA
and 6-OHDA + AE (300 mg/kg) groups (p < 0.0001)
and 6-OHDA + AE (150 mg/kg) and 6-OHDA + AE
(300 mg/kg) groups (p < 0.0001) (Fig. 1).
Effect of Albizia adianthifolia extract on elevated plus-
maze behavior
As can be seen in Fig. 2a, in the elevated plus-maze
ANOVA revealed a significant increase of the percentage
of the time spent in the open arms in 6-OHDA-lesioned
groups treated with low-and high-doses (150 and
300 mg/kg) of the aqueous extract of A. adianthifolia
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leaves (F(3,36) = 3.51, p < 0.05), suggesting significant anxio-
lytic effects. Additionally, Tukey’s post hoc analysis revealed
a significant difference between the control and 6-OHDA
groups (p < 0.05), control and 6-OHDA+AE (150 mg/kg)
groups (p < 0.05), control and 6-OHDA+AE (300 mg/kg)
groups (p < 0.01), DIAZ and 6-OHDA groups (p < 0.05),
DIAZ and 6-OHDA+AE (150 mg/kg) groups (p < 0.001),
DIAZ and 6-OHDA+AE (300 mg/kg) (p < 0.001), 6-
OHDA and 6-OHDA+AE (150 mg/kg) groups (p < 0.01)
and 6-OHDA and 6-OHDA + AE (300 mg/kg) groups
(p < 0.01) (Fig. 2a) for the percentage of the time spent
in the open arms, indicating that the aqueous extract of
A. adianthifolia leaves has anxiolytic-like profile. Non-
significant differences between control and DIAZ were
observed (p > 0.05).
As can be seen in Fig. 2b, in the elevated plus-
maze ANOVA revealed a significant increase of the
number of open-arm entries in 6-OHDA-lesioned
groups treated with low-and high-doses (150 and
300 mg/kg) of the aqueous extract of A. adianthifolia
leaves (F(3,36) = 8.03, p < 0.001), suggesting significant
anxiolytic effects. Additionally, Tukey’s post hoc analysis
revealed a significant difference between the control
and 6-OHDA groups (p < 0.001), control and 6-OHDA
+ AE (150 mg/kg) groups (p < 0.05), control and 6-
OHDA + AE (300 mg/kg) groups (p < 0.01), DIAZ and
6-OHDA groups (p < 0.05), 6-OHDA and 6-OHDA +
AE (150 mg/kg) groups (p < 0.0001) and 6-OHDA and
6-OHDA + AE (300 mg/kg) groups (p < 0.001) (Fig. 2b)
for the number of open-arm entries, indicating that the
aqueous extract of A. adianthifolia leaves has anxiolytic-
like profile as suggested above. Non-significant differences
between control and DIAZ were observed (p > 0.05).
As can be seen in Fig. 2c, in the elevated plus-maze
ANOVA revealed a significant increase on the explora-
tory locomotor activity in 6-OHDA-lesioned groups
treated with low-and high-doses (150 and 300 mg/kg)
of the aqueous extract of A. adianthifolia leaves
(F(3,36) = 48.87, p < 0.0001), as evidenced by the number
of crossing. Additionally, Tukey’s post hoc analysis
revealed a significant difference between the control and
DIAZ groups (p < 0.0001), control and 6-OHDA groups
(p < 0.05), control and 6-OHDA+AE (150 mg/kg) groups
(p < 0.01), control and 6-OHDA+AE (300 mg/kg) groups
(p < 0.01), DIAZ and 6-OHDA groups (p < 0.0001), DIAZ
and 6-OHDA +AE (150 mg/kg) groups (p < 0.0001),
DIAZ and 6-OHDA +AE (300 mg/kg) groups (p <
0.0001), 6-OHDA and 6-OHDA+AE (150 mg/kg) groups
(p < 0.01) and 6-OHDA and 6-OHDA+AE (300 mg/kg)
groups (p < 0.01) (Fig. 2c) for the number of crossing.
Also, significant differences between control and DIAZ
were observed (p < 0.0001).
Effect of Albizia adianthifolia extract in the rat forced
swimming test
In the forced swimming test, ANOVA revealed a
significant effect on depressive-like response in 6-
OHDA-lesioned groups treated with low-and high-doses
(150 and 300 mg/kg) of the aqueous extract of A.
adianthifolia leaves, as evidenced by the swimming time
(F(3,36) = 21.09, p < 0.0001) (Fig. 3a) and the immobility
time (F(3,36) = 78.59, p < 0.0001) (Fig. 3b). Additionally,
Tukey’s post hoc analysis revealed significant differences
between the control and TRM groups (p < 0.0001), con-
trol and 6-OHDA groups (p < 0.0001), control and 6-
OHDA +AE (150 mg/kg) groups (p < 0.0001), control
and 6-OHDA +AE (300 mg/kg) groups (p < 0.0001),
TRM and 6-OHDA groups (p < 0.05), 6-OHDA and 6-
OHDA+AE (150 mg/kg) groups (p < 0.01), 6-OHDA
and 6-OHDA +AE (300 mg/kg) groups (p < 0.01) and 6-
OHDA +AE (150 mg/kg) and 6-OHDA +AE (300 mg/
kg) groups (p < 0.01) for the swimming time (Fig. 3a).
Moreover, Tukey’s post hoc analysis revealed significant
differences between the control and TRM groups (p < 0.01),
control and 6-OHDA groups (p < 0.0001), TRM and 6-
OHDA groups (p < 0.0001), 6-OHDA and 6-OHDA+AE
(150 mg/kg) groups (p < 0.0001) and 6-OHDA and 6-
OHDA+AE (300 mg/kg) groups (p < 0.0001) for the
immobility time (Fig. 3b).
Fig. 1 Protective effects of the aqueous extract of Albizia
adianthifolia leaves (150 and 300 mg/kg) on pergolide (0.5 mg/kg,
b.w., s.c.)-induced rotational behavior in 6-OHDA-lesioned rats. 1 week
after 6-OHDA injection, the number of net rotation contralateral to the
lesion side was increased. However, the administration of the aqueous
extract restored the decrease in the number of net rotation.
Values are means ± S.E.M. (n = 10 animals per group), **p < 0.001,
***p < 0.0001 vs. 6-OHDA alone treated-group
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Effect of Albizia adianthifolia extract on SOD, GPX and
CAT activities
For SOD specific activity estimated in the rat amyg-
dala homogenates, ANOVA revealed a significant
overall effect (F(3,36) = 42.68, p < 0.0001) (Fig. 4a).
Additionally, Tukey’s post hoc analysis revealed signifi-
cant differences between the control and 6-OHDA
groups (p < 0.01), control and 6-OHDA + AE (150 mg/
kg) groups (p < 0.0001), control and 6-OHDA + AE
(300 mg/kg) groups (p < 0.01), 6-OHDA and 6-OHDA
Fig. 2 Effects of the aqueous extract of Albizia adianthifolia leaves (150 and 300 mg/kg) in the elevated plus-maze test on a the percentage of
the time spent in the open arms, b the number of open-arm entries and c the number of crossing in the 6-OHDA-treated rats. Values are means
± S.E.M. (n = 10 animals per group), **p < 0.01, vs. 6-OHDA alone treated-group
Fig. 3 Effects of the aqueous extract of Albizia adianthifolia leaves (150 and 300 mg/kg) on a swimming time and b immobility time in the
6-OHDA-treated rats during the 6 min period in the forced swimming test. Values are means ± S.E.M. (n = 10 animals per group),
**p < 0.01 vs. 6-OHDA alone treated-group
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+ AE (150 mg/kg) groups (p < 0.0001), 6-OHDA and
6-OHDA + AE (300 mg/kg) groups (p < 0.001) and 6-
OHDA + AE (150 mg/kg) and 6-OHDA + AE (300 mg/
kg) groups (p < 0.0001) for SOD specific activity.
For GPX specific activity estimated in the rat amygdala
homogenates, ANOVA revealed a significant overall
effect (F(3, 36) = 40.20, p < 0.0001) (Fig. 4b). Additionally,
Tukey’s post hoc analysis revealed significant differ-
ences between the control and 6-OHDA + AE
(150 mg/kg) groups (p < 0.0001), control and 6-
OHDA + AE (300 mg/kg) groups (p < 0.001), 6-OHDA
and 6-OHDA + AE (150 mg/kg) groups (p < 0.0001)
and 6-OHDA and 6-OHDA + AE (300 mg/kg) groups
(p < 0.001) for GPX specific activity.
For CAT specific activity estimated in the rat amyg-
dala homogenates, ANOVA revealed a significant
overall effect (F(3, 36) = 35.40, p < 0.0001) (Fig. 4c).
Additionally, Tukey’s post hoc analysis revealed
significant differences between the control and 6-
OHDA groups (p < 0.001), control and 6-OHDA + AE
Fig. 4 Effects of the aqueous extract of Albizia adianthifolia leaves (150 and 300 mg/kg) on a SOD, b GPX and c CAT specific activities, on d total
content of reduced GSH, e protein carbonyl and f MDA levels in the 6-OHDA-treated rats. Values are means ± S.E.M. (n = 10 animals per group),
**p < 0.001, ***p < 0.0001 vs. 6-OHDA alone treated-group
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(150 mg/kg) groups (p < 0.001), 6-OHDA and 6-OHDA+
AE (150 mg/kg) groups (p < 0.0001), 6-OHDA and 6-
OHDA+AE (300 mg/kg) groups (p < 0.001) and 6-OHDA
+AE (150 mg/kg) and 6-OHDA+AE (300 mg/kg) groups
(p < 0.001) for CAT specific activity.
Effect of Albizia adianthifolia extract on total content of
reduced GSH, protein carbonyl and MDA levels
For the total content of reduced GSH estimated in
the rat amygdala homogenates, ANOVA revealed a
significant overall effect (F(3, 36) = 41.79, p < 0.0001)
(Fig. 4d). Additionally, Tukey’s post hoc analysis re-
vealed significant differences between the control and
6-OHDA groups (p < 0.01), control and 6-OHDA + AE
(150 mg/kg) groups (p < 0.0001), control and 6-
OHDA + AE (300 mg/kg) groups (p < 0.001), 6-OHDA
and 6-OHDA + AE (150 mg/kg) groups (p < 0.0001)
and 6-OHDA vs. 6-OHDA + AE (300 mg/kg) groups
(p < 0.0001) for the total content of reduced GSH.
For the protein carbonyl level ANOVA revealed a sig-
nificant overall effect (F(3, 36) = 5.19, p < 0.01) (Fig. 4e).
Additionally, Tukey’s post hoc analysis revealed signifi-
cant differences between the control and 6-OHDA
groups (p < 0.01), control and 6-OHDA +AE (150 mg/
kg) groups (p < 0.01), control and 6-OHDA +AE
(300 mg/kg) groups (p < 0.01) and 6-OHDA and 6-
OHDA+AE (300 mg/kg) groups (p < 0.001) for protein
carbonyl level.
For the MDA level ANOVA revealed a significant
overall effect (F(3, 36) = 8.48, p < 0.001) (Fig. 4f ). Add-
itionally, Tukey’s post hoc analysis revealed significant
differences between the control and 6-OHDA groups
(p < 0.001), 6-OHDA and 6-OHDA + AE (150 mg/kg)
groups (p < 0.001) and 6-OHDA and 6-OHDA + AE
(300 mg/kg) groups (p < 0.01) for MDA level.
These results support the hypothesis that the aqueous
extract of A. adianthifolia leaves may have induced a de-
crease in neuronal oxidative stress.
More importantly, when linear regression was deter-
mined, significant correlations between the number of
entries in the open arms vs. MDA (n = 40, r = −0.791,
p < 0.001) (Fig. 5a), the number of crossing vs. MDA
(n = 40, r = −0.872, p < 0.001) (Fig. 5b) were evidenced.
Additionally, a significant correlation was evidenced
by determination of the linear regression between
SOD vs. MDA (n = 40, r = −0.632, p < 0.01) (Fig. 5c),
GPX vs. MDA (n = 40, r = −0.675, p < 0.01) (Fig. 5d),
CAT vs. MDA (n = 40, r = −0.855, p < 0.0001) (Fig. 5e)
and GSH vs. MDA (n = 40, r = −0.771, p < 0.0001)
(Fig. 5f ).
These data suggest that anxiolytic responses within el-
evated plus-maze a and increase of the antioxidant
defence along with decrease of lipid peroxidation could
related with the involvement of the aqueous extract of
A. adianthifolia leaves in neuroprotection against 6-
OHDA-induced neuronal oxidative stress generation.
Effect of Albizia adianthifolia extract on DNA
fragmentation
In our study, DNA cleavage patterns were absent in the
aqueous extract groups as compared to 6-OHDA alone-
treated group (Fig. 6), suggesting that the aqueous extract
of A. adianthifolia leaves do not induce neurotoxicity and
this effect could be related to its antioxidant activity.
Discussion
The present study was aimed to examine the anxiety-like
behavior and depressive-like response following adminis-
tration of the aqueous extract of A. adianthifolia leaves in
rats subjected to intranigral injection of 6-OHDA. It has
been reported that 6-OHDA-induce lesion of the striatum
causes depression- and anxiety-like behavior [34].
Previously, we have reported apigenin as the main
component of the aqueous extract of A. adianthifolia
leaves [16]. Several studies indicated anxiolytic and anti-
depressant activity of apigenin in rats exposed to behav-
ioral tests [35]. Moreover, it is reported that apigenin
modulates the γ-aminobutyric acid (GABA)ergic system
to produce the biological effect .
PD is accompanied by non-motor symptoms, includ-
ing olfactory loss, cognitive decline, depression and anx-
iety, which frequently appear in the early stages or even
during the premotor phase of the disease [34]. Psychi-
atric symptoms have been related to monoaminergic
deficits within components of the limbic system impli-
cated in emotional and affective functions. In fact, the
progressive death of midbrain dopaminergic neurons in
PD is paralleled by the concomitant degeneration of nor-
adrenergic and serotonergic systems [36].
The 6-OHDA lesion used in this study affects both
dopamine and noradrenaline innervation [34]. There-
fore, to assess the contribution of these systems to anx-
iety and depression conditions, we limited the lesion
with 6-OHDA to the dopamine neurons by pre-treating
the rats with the selective noradrenaline reuptake in-
hibitor, desipramine. In addition, the pergolide results
confirm the impairment of the dopaminergic system.
Our data show that intranigral unilateral injection
of 6-OHDA significantly decreased the percentage of
the time spent in the open arms and the number of
open-arm entries in the elevated plus maze test, two
indicative parameters of anxiety. This indicates that
the 6-OHDA-treated rats experienced high levels of
anxiety and were suitable for evaluating the pre-
sumed anxiolytic substances. Notably, we found that
administration of the aqueous extract (150 mg/kg
and 300 mg/kg) counteracts anxiety of rats produced
by the 6-OHDA lesion, suggesting potent anxiolytic
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effects. These results are strengthened by the fact
that the benzodiazepine diazepam (DZP), well-known
as positive standard anxiolytic [37], was used as
positive control comparatively to the aqueous extract
in all of our experimental conditions. DZP produced
significant increases of the number of open-arm en-
tries and in the number of crossing, while the per-
centage of time spent in the open arms was
decreased as compared to control group. These data
are consistent with the results of numerous previous
studies, which have shown that DZP and other ben-
zodiazepines produce significant anxiolytic effects in
a variety of anxiolytic screening procedures, includ-
ing elevated plus‐maze test procedures [38]. The
pharmacological action of diazepam enhances the ef-
fect of the neurotransmitter GABA by binding to the
benzodiazepine site on the GABAA receptor (via the
constituent chlorine atom) leading to central nervous
Fig. 5 Pearson’s correlation between a the number of entries in the open arms vs. MDA, b the number of crossing vs. MDA, c SOD vs. MDA, d
GPX vs. MDA, e CAT vs. MDA and f GSH vs. MDA in control group (●), 6-OHDA alone treated-group (■), 6-OHDA + AE (150 mg/kg) group (♦) and
6-OHDA + AE (300 mg/kg) group (▲)
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system (CNS) depression. The anxiety indicators in
the elevated plus-maze (the percentage of the time
spent in the open arms and the number of open-arm
entries) showed up being sensitive to the agents
which were thought to act via the GABAA receptor
complex [39].
The anxiolytic-like effects of the aqueous extract could
be explained by the presence of apigenin in large
amounts, as previously evidenced by HPLC analysis [16].
However, it is suggested that apigenin has a clear
anxiolytic-like effect in mice, without evidencing sed-
ation or muscle relaxation effects. This effect could be
mediated by the action of GABA receptor complex [40].
In agreement with these reports, our high-apigenin con-
taining aqueous extract has increased anxiolytic-like be-
havior and exploratory activity in 6-OHDA-treated rats.
The forced swimming test has been validated as a
suitable tool for predicting the antidepressant proper-
ties of drugs [41]. When rodents are forced to swim in
a confined space, after an initial period of struggling,
they would become immobile, resembling a state of
despair and mental depression. This inescapable
stressful situation can be evaluated by assessing differ-
ent behavioral strategies [42].
Our data suggest that 6-OHDA increased the immo-
bility time in the forced swimming test, a standard
behavioral paradigm indicative of depression [34]. These
findings are in line with a previous study performed in
the 6-OHDA-lesioned rat [43]. Moreover, we found that
treatment with the aqueous extract (150 mg/kg and
300 mg/kg) effectively reverted the increase of the im-
mobility time and prolonged the swimming time dis-
played by the 6-OHDA-lesioned rats. We used tramadol
as a positive control in the aqueous extract assay for all
of our experimental conditions. Tramadol has been
studied in the forced swimming test in rats, a test devel-
oped to predict the antidepressant action of drugs [44].
Tramadol is a unique drug with multiple modes of ac-
tion. It is a weak agonist of the μ-opioid receptor but it
also inhibits the reuptake of serotonin as well as nor-
epinephrine. It is an analgesic and it is also considered
as an antidepressant [45]. Also, tramadol exhibited sig-
nificant effects on the immobility time while swimming
time was decreased as compared to control group.
Oxidative stress enhancement also plays a pivotal role
in 6-OHDA-neurotoxicity in experimental models of PD
[46]. There is increasing evidence that oxidative stress
due to increased generation of reactive oxygen species is
strongly involved in the pathogenesis of PD, suggesting
that pharmacological targeting of the antioxidant ma-
chinery may be of benefit in PD therapy [47]. Since 6-
OHDA leads to the production of both H2O2 and
superoxide radicals, decreasing of SOD activity leads to
6-OHDA-induced toxicity. Similarly, a decrease of GPX
activity may be a cause of a decrease in the levels of
GSH, because 6-OHDA induced cytotoxicity via H2O2
intracellular production which can be transformed in
reactive hydroxyl radicals and produce cell damage [48].
The aqueous extract of A. adianthifolia leaves in the two
doses used, reestablished the specific activities of SOD,
GPX and CAT, increased GSH level along with
decreased lipid peroxidation (MDA level) and protein
oxidation (protein carbonyl level) in the amygdala
homogenates. The increased activities of SOD, GPX,
CAT, GSH level and the decreased levels of protein
carbonyl and MDA induced by administration of the
aqueous extract of A. adianthifolia leaves, implying that
this plant extract possesses strong antioxidant property.
The antioxidants SOD and GSH have a certain anti-
depressant effect. Thus, anti-oxidation features in organ-
isms are considered one way to resist depression [49].
The antioxidant effect observed could be attributed to
apigenin the only flavonoid that was quantified [16]. Our
finding are in line with other studies in which apigenin
strongly scavenged the ROS overproduction and pro-
vided sufficient antioxidant effect by improving the
Fig. 6 Effects of the aqueous extract of Albizia adianthifolia
leaves (150 and 300 mg/kg) DNA fragmentation by agarose
(1.5 %) gel electrophoresis. Lane 1: DNA ladder; lane 2: control
group; lane 3: 6-OHDA alone treated-group; lane 4: 6-OHDA + AE
(150 mg/kg) group and lane 5: 6-OHDA + AE (300 mg/kg) group
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antioxidative enzymes activity [11]. Also, apigenin was
found to exert a variety of pharmacological actions on
the central nervous system, such as anxiolytic and seda-
tive properties [50]. Therefore, the observed effects of
our plant extract could be attributed at least partially to
apigenin.
Additionally, when linear regression was determined,
a significant correlation between the number of en-
tries in the open arms vs. MDA, the number of cross-
ing vs. MDA, SOD vs. MDA, GPX vs. MDA, CAT vs.
MDA and GSH vs. MDA was observed. These results
may suggest that the increase of anxiolytic responses
within elevated plus-maze and the antioxidant defence
along with decrease of lipid peroxidation could be cor-
related with involvement of the aqueous extract in
neuroprotection against 6-OHDA-induced oxidative
stress generation in the rat amygdala. Also, we re-
ported the absence of DNA cleavage patterns in the
amygdala of the 6-OHDA-treated rats after adminis-
tration of the aqueous extract, suggesting that the
aqueous extract doesn’t possesses neurotoxic effects.
Regarding the limitation of our study we can add that
there is an indirect behavioral evidence (e.g. rotational
behavior) that the lesion worked rather than neurochem-
istry of the substantia nigra to confirm the size of lesion.
Conclusions
In summary, the aqueous extract of A. adianthifolia leaves
has anxiolytic and antidepressant effects, and may confer
neuroprotection due to alleviation of oxidative stress in
the rat amygdala induced by 6-OHDA injection. Further-
more, administration of the aqueous extract might offer a
useful alternative or complementary choice in either the
prevention or the treatment of psychiatric condition with
relevance for PD.
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